However, I think it was a strategic mistake setting expectations so high,” he said. New trial Martin Holst Lange, Novo ...

Despite these setbacks, Novo Nordisk said it remains committed to CagriSema ... both semaglutide and cagrilintide in ...

Martin Holst Lange, Novo Nordisk's head of development, pointed out that only 57% of patients had received the highest dose of CagriSema, asserting that the company remains "encouraged by the ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Bad news for Novo Nordisk (NVO-1.99% ... 1 trial," said Novo's Executive Vice President for Development Martin Lange, noting that the company plans to "further explore the additional weight ...

Within Novo Nordisk's comprehensive business update ... The company's head of development, Martin Lange Holst, told the meeting that the promising results justify further research and a larger ...

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and ... in monotherapy,” Martin Holst Lange, executive vice president ...

Novo Nordisk egen forventning var 25 procent, lød det fra forskningschef Martin Holst Lange for to år siden, skriver det svenske nyhedsbureau Direkt. I marts nedjusterede Novo så de forventninger til ...

Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data. He said only 57% of patients in the trial reached the highest dose.

Despite falling short of previously announced targets Novo Nordisk is still positive on meeting the primary endpoint of efficacy over placebo. Martin Holst Lange, executive vice president for ...